Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (August 2020)
30 slides from Aim Immunotech's investor presentation, Aug 3, 2020
Slide 1: Ampligen's Update in COVID-19, ME/CFS, COVID-19 Induced Fatigue and Immuno-oncology
SAI ImmunoTech Ampligen’s Update in COVID-19, ME/CFS, COVID-19 Induced Fatigue and Immuno-oncology Alferon Manufacturing Update
Slide 2: Forward-Looking Statements
Forward-Looking Statements Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private
Slide 3: AIM ImmunoTech Inc. Overview
AIM ImmunoTech Inc. Overview e — AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of viral diseases, cancers, and immune-deficiency disorders e AIM ImmunoTech’s flagship products include Ampligen® (rintatolimod) and Alfer
Slide 4: Investment Highlights
Investment Highlights v¥ Advancing clinical trials of Ampligen as a potential protective prophylaxis and an early-onset treatment for COVID-19 v Japan evaluating Ampligen as a potential COVID-19 vaccine adjuvant v Ampligen believed to be the world’s only approved therapeutic for ME/CFS (first approv
Slide 5: Pipeline in Oncology, COVID-19 and ME/CFS
Pipeline in Oncology, COVID-19 and ME/CFS pn Troproacn | tnsttaton | mre-cincal | phases | Phase2 | phases | approval Sie hoe SSE) ME]CES sa ‘Approved in Argentina ‘i: Chemokine P1/2 Ovarian Cancer Paras QR — ——E—E—E—EE Advanced, Recurrent Regimen pape tetea P22) Colbrectalicalicer Modulotory CS —EE
Slide 6: Ampligen is a Broad-Spectrum Antiviral
Ampligen is a Broad-Spectrum Antiviral e Ampligen has demonstrated antiviral activity against a broad spectrum of viruses, including Herpes viruses, Alphaviruses, Coronaviruses and Filoviruses. e Ampligen has shown a survival benefit in Alphaviruses, Coronaviruses, Filoviruses and Paramyxoviruses in
Slide 7: Ampligen as a Potential Tool to Fight COVID-19
Ampligen as a Potential Tool to Fight COVID-19 Following the SARS-CoV-1 outbreak in 2002-03, Ampligen exhibited excellent antiviral properties and protective survival effect in NIH-contracted studies of SARS-infected mice, which is almost identical to SARS-CoV-2. * The Barnard 2006 study (https://jo
Slide 8: Researching Ampligen's Potential as a Protective Prophylaxis and Early-onset Treatment for COVID-19
Researching Ampligen’s Potential as a Protective Prophylaxis and an Early-onset Treatment for COVID-19 ..@ Prophylaxis for first responders and other medical professionals to essentially armor themselves against the virus before treating new and potential patients ..an Early-onset Therapeutic for pe
Slide 9: Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19
Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer e Signed clinical trial agreement with Roswell Park Comprehensive Cancer Center supporting Phase 1/2 clinical trial of Ampligen combined with Interferon Alfa-2b in COVID-19 patients with cancer e R
Slide 10: Additional Advancements in COVID-19
Additional Advancements in COVID-19 e Filed provisional patent application for the use of Ampligen as a potential therapy for COVID-19 induced chronic fatigue e Signed material transfer and research agreement with Japan's National Institute of Infectious Diseases (NIID) and Shionogi, a leading globa
Slide 11: Ampligen in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ampligen in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) e 10 years ago, the medical consensus was that ME/CFS was a psychological disorder e Peer-reviewed medical journal articles now support the proposition that ME/CFS is in fact a medical disorder rooted in the immune system e Heig
Slide 12: Ampligen in ME/CFS
Ampligen in ME/CFS e Based upon Phase 2 and 3 clinical trial data, received commercial approval for Ampligen in the treatment of severe ME/CFS in Argentina in 2016 e Trial data served as the basis for an FDA complete response letter in 2013 requiring an additional Phase 3 confirmatory trial, despite
Slide 13: COVID-Induced Chronic Fatigue: COVID Survivor Syndrome
COVID-Induced Chronic Fatigue: “COVID Survivor Syndrome” © "It is anticipated that COVID-19 will trigger a large number of CFS cases, providing an opportunity for the medical community to learn more about the onset and pathogenesis of CFS. The investigational immune-modulating antiviral drug Amplige
Slide 14: Ampligen and Immuno-Oncology
Ampligen and Immuno-Oncology SaiM ImmunoTech
Slide 15: Animal Experiments: Ampligen + Checkpoint Blockade Synergistically Increased Survival
Animal Experiments: Ampligen + Checkpoint Blockade Synergistically Increased Survival/Anti-tumor Response Synergistic/anti-tumor responses at three different university centers using 3 different animal models in 3 different solid tumors have led to new collaborations: ° AnAIM grant experiment at the
Slide 16: Ongoing Clinical Trial Objective: Convert 'Cold' Tumors Into 'Hot'
Ongoing Clinical Trial Objective: Prove Ampligen Converts ‘Cold’ Tumors Into ‘Hot’ Tumors that will be Responsive to Checkpoint Inhibitors Increase Intratumoral Effector T (Teff) cells e Decrease Intratumoral Regulatory T (Treg) cells e Goal is to unleash the cellular immune response to attack and d
Slide 17: Six Ampligen Immuno-Oncology Clinical Trials Initiated / Ongoing in the U.S.
Six Ampligen Immuno-Oncology Clinical Trials Initiated / Ongoing in the U.S. e Advanced Recurrent Ovarian Cancer - Phase 1 / 2 study of intraperitoneal chemo- immunotherapy in advanced recurrent ovarian cancer; Phase 1 portion establishes UPMC intraperitoneal safety. Awaiting publication of Phase |
Slide 18: Six Ampligen Immuno-oncology Clinical Trials Initiated / Ongoing in the U.S.
Six Ampligen Immuno-oncology Clinical Trials Initiated / Ongoing in the U.S. e Stage 4 Colorectal Cancer Metastatic to the Liver - Phase 2a study of Ampligen as component of chemokine modulatory regimen on colorectal cancer metastatic to liver; the majority of the 12 planned patients enrolled and tr
Slide 19: Major Grant Awards
Major Grant Awards e National Cancer Institute’s award of $14.5 million to Roswell Park to study Ampligen as part of five Roswell park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers « U.S. Department of Defense-funded Clinical Trial in Brain-Metastatic Breast Ca
Slide 20: Expanded Access Program with Ampligen as Standalone Treatment in Pancreatic Cancer
Expanded Access Program (EAP) with Ampligen as Standalone Treatment in Pancreatic Cancer (Completed Except for Final Report) ° Location: Erasmus University, The Netherlands conducted by Professor Casper van Eijck e — Eligibility: Adults with metastatic or locally advanced pancreatic carcinoma follow
Slide 21: Alferon N Injection (interferon alfa-n3)
Alferon N Injection (interferon alfa-n3) ¢ Approved in the U.S. for the treatment of refractory or recurrent external genital warts in patients ages 18 or older ° Reimbursement approved by major insurers for all refractory patients ° Incidence of neutralizing antibodies induced against Alferon is ve
Slide 22: Alferon N Injection Development Pipeline
Alferon N Injection Development Pipeline Pre- ene _ Genital HPV US and (condylomata acuminata) Argentina Refractory to Recombinant IFN v v Argentina v he. ee Intolerant to Recombinant IFN Argentina MERS* S BS S Bs Influenza A (H7N9) Virus * Orphan Drug Indication in EU S Al M NYSE American: AIM Immu
Slide 23: IP Protection and Growing Patent Estate
IP Protection and Growing Patent Estate * 48 patents worldwide with 11 additional pending patent applications underway ° FDA granted Ampligen “orphan drug status” for CFS, HIV/AIDS, renal cell carcinoma and malignant melanoma ° Grants protection against potential subsequent approval of other version
Slide 24: Proven Management Team
Proven Management Team ° Thomas K. Equels, M.S., J.D. / Chief Executive Officer — Equels was named Chief Executive Officer in February 2016 and has served as President since August 2015. Equels’ successful legal career included extensive experience in the pharma sector. He has over the years served
Slide 25: 2020 AIM ImmunoTech Stock Activity
2020 AIM IMMUNOTECH STOCK ACTIVITY closing Price, Last Trading Day of Month Linear (Closing Price, Last Trading Day of Month) Average Daily Volume: 5,762,356 Shares “Per Yahoo Finance, 7/31/20 Salm ImmunoTech NYSE American: AIM 25
Slide 26: Cap Table (As of 3/31/20)
Cap Table (As of 3/31/20) | # of Shares Common Equivalent % of Fully Diluted Outstanding shares of common stock 384,672 384,672 1.4% owned by Officers and Directors Common Shares Outstanding (including 27,626,077 27,626,077 97.1% Officers and Directors) Series B Convertible Preferred 17 87,386 0.3%
Slide 27: Key Statistics
Key Statistics ¢ Ticker: AIM » Exchange: NYSE American + Share Price (07/31/20) $2.92 » Shares Outstanding (06/12/20) 32.62 M « Market Cap (07/31/20)* $95.25 M * Cash and Cash Equivalents (03/31/20): $31.3 M + Security Ownership of Management (03/31/20): 1.4% * Market Cap calculated using shares out
Slide 28: Supplemental Data: Immunological Activity
Supplemental Data: Immunological Activity Only TLR3 agonist to promote selective attraction of CTLs (Teff) with concomitant increase in Teff/Treg ratio in the TME Reference(s)* Theodoraki, et al. (2018) Ampligen induces desirable chemokines in the TME, while other TLR3 agonists, such as poly IC, by
Slide 29: Supplemental Data: Immunological Activity
Supplemental Data: Immunological A ity Induces dendritic cell maturation: Enhances bioactivity of cancer immunotherapy Reference(s)* Nicodemus, et al. (2010) Promotes optimal dendritic cell maturation and Th1-type responses of healthy donors and cancer patients in vivo Navabi, et al. (2009) Induces
Slide 30: Supplemental Data: Antiviral Activity
Supplemental Data: Ac ity Ampligen increases exercise performance in ME/CFS in Phase Ill, placebo-controlled trial References Strayer, et al. (2012) Review of Ampligen clinical activity in ME/CFS Mitchell (2016) Low NK cell activity in ME/CFS increased by Ampligen (in vitro) Strayer, et al. (2015) A